Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the App...
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
About this item
Full title
Author / Creator
Publisher
United States: College of American Pathologists
Journal title
Language
English
Formats
Publication information
Publisher
United States: College of American Pathologists
Subjects
More information
Scope and Contents
Contents
Regulatory approval of pembrolizumab for treatment of gastric and gastroesophageal junction (G/GEJ) adenocarcinoma required a reproducible scoring method for use of programmed death ligand-1 (PD-L1) protein expression as a companion diagnostic to identify likely responders to therapy.
To develop an immunohistochemical scoring algorithm that incl...
Alternative Titles
Full title
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2073319091
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2073319091
Other Identifiers
ISSN
0003-9985,1543-2165
E-ISSN
1543-2165
DOI
10.5858/arpa.2018-0043-OA
